Skip to content

Neon stock price target

Neon stock price target

Neonode (NasdaqCM:NEON) - Share price, News & Analysis ... Neonode Inc., together with its subsidiaries, develops and licenses user interface and optical interactive touch solutions under the zForce brand in the United States, Japan, Germany, China, Taiwan, South Korea, and internationally. NTGN Stock Price & Charts | Neon Therapeutics In depth view into NTGN (Neon Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. NEON THERAPEUTICS, INC. : NTGN Stock Price | MarketScreener

Product Pipeline - Neon

NEON Price Target | Neonode Stock Forecast & Ratings See Neonode price target based on analysts offering 12 month price targets for Neonode in the last 3 months. Follow NEON to track price target and stock forecast updates from top wall street analysts.

Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer.

2 equities research analysts have issued 12 month price targets for Neonode's shares. Their forecasts range from $1.50 to $15.00. On average, they expect  Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Neonode Inc have a median target of 3.00, with a high estimate of 3.00 and a low  

Apr 14, 2019 · Price Target: A price target is the projected price level of a financial security stated by an investment analyst or advisor . It represents a security's price that, if achieved, results in a

Previously, the target price had yet another raise to $15, while Robert W. Baird analysts kept a Outperform rating on NTGN stock. The Average True Range (ATR) for Neon Therapeutics Inc. is set at 0.21 The Price to Book ratio for the last quarter was 2.50, with the Price to … XSPA XpresSpa GroupStock — Stock Price and Discussion ... Apr 03, 2020 · Market Data by Xignite and BATS BZX Real-Time Price. Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, Neon Therapeutics (NASDAQ:NTGN) Given “Neutral” Rating at ... Zacks Investment Research upgraded shares of Neon Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Saturday, January 4th. Robert W. Baird downgraded shares of Neon Therapeutics from an “outperform” rating to a “neutral” rating in a report on Thursday, January 16th. Are Neon Therapeutics’ Shareholders Getting Enough in the ... Jan 16, 2020 · The implied price of $2.18 per Neon share offers a premium of 65% from the stock’s 50-day moving average ($1.32). However, this is a 33% discount from the 200-day trading average ($3.25).

Product Pipeline Neon Therapeutics is developing novel neoantigen-targeted T cell therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both personal and precision neoantigen-targeted T …

Are Neon Therapeutics’ Shareholders Getting Enough in the ... Jan 16, 2020 · The implied price of $2.18 per Neon share offers a premium of 65% from the stock’s 50-day moving average ($1.32). However, this is a 33% discount from the 200-day trading average ($3.25).

Apex Business WordPress Theme | Designed by Crafthemes